Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease
Biogen (United States) · University of Southern California · +9 more institutions
Indexed incrossrefdoajpubmed
Abstract
Background
Alzheimer's disease is a progressive, irreversible, and fatal disease for which accumulation of amyloid beta is thought to play a key role in pathogenesis. Aducanumab is a human monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta.
Objectives
We evaluated the efficacy and safety of aducanumab in early Alzheimer's disease.
Citation impact
1,297
total citations
- FWCI
- 140.42
- Percentile
- 100%
- References
- 30
Citations per year
Authors
24- SBSamantha Budd HaeberleinCorresponding
Biogen (United States)
- PAPaul Aisen
University of Southern California
- FBFrederik Barkhof
National Hospital for Neurology and Neurosurgery, Amsterdam University Medical Centers, University College London
- SCSpyros Chalkias
Biogen (United States)
- TCTianle Chen
Biogen (United States)
Topics & keywords
Topics
Keywords
- Medicine
- Placebo
- Clinical endpoint
- Dementia
- Disease
- Alzheimer's disease
- Internal medicine
- Clinical trial
No related works found for this paper.
Funding
- FFFoundation for the National Institutes of Health
- AAAlzheimer's Association
- ELEli Lilly and Company
- PPfizer
- BBiogen
- MModerna
- NINational Institute for Health and Care Research
- EEisai
- UDUniversité de Toulouse
- UCUniversity College London Hospitals NHS Foundation Trust
- IIXICO
- NINational Institutes of Health
- GGenentech
- ARAvid Radiopharmaceuticals